UNITED PHARMACY: COMMITTED TO ACCESSIBILITY & AFFORDABILITY THROUGH ASSOCIATION WITH
THE 340-B PROGRAM

– Providing the highest customer/client service to SIGNIFICANT drug discounts & assurance of
compliance with federal regulation.
ACCESS to SPECIALTY DRUG DISCOUNT & COMPLIANT Health care groups/hospitals
PROVIDING keys through affordable access to drugs serving:
HEPATITIS C MANAGEMENT:
Hepatitis C Virus (HCV) is the most common blood born pathogen and also the leading cause of liver
cancer (and need for liver transplants) in the United Status. While common, HCV currently has low
treatment and cure rates due to the accessibility of drug treatment, despite the creation of Direct Acting
Antivirals which is shown to see higher rate of cure, less side effects and shorter need of treatment.
Participation in the treatment of HCV has been difficult due to a number of barriers. To start, providers
have the challenge of the cost of therapy and obtaining the approval and authorization of he therapy.
Next, patients often times experience their own barriers due to proper understanding of and compliance
with the therapy and, even overcoming fear associated with possible side effects of therapy. Another
challenge facing HCV patients includes the combinations of medication prescribed, as often times
patients have comorbid conditions that lead to challenges in drug interactions.
Commonly, patients with chronic HCV face the complex obstacles of treatment coupled with possible
mental health issues, addiction, and even times HIV/AIDS. This coupled with aging populations of
patients with HCV further increases the complexity of treatment as well as impacting the socioeconomic
factors and challenges associated with funding treatment, success and support necessary for successes.
Participation with 340 B programs is fundamental to treating these patients as without the discounts
associated with the program, most patients simply cannot afford life-saving treatment.

 

HIV MANAGEMENT:

HIV patients have long experienced a complicated path to treatment. Their journey has been
compounded by fact that funding their therapy and prescriptions has been increasingly difficult and
uncertain.
For providers, HIV patients can be challenging. HIV treatment has evolved greatly over the past years,
however the proper “formula” in treatment is complicated. Often times, patients are prescribed an
interdisciplinary form of treatment that monitors barriers that may present due to interactions amongst
medications. Due to the complexity of the disease, most HIV patients see multiple doctors, however,
their medications should be filled by one common pharmacy so as the pharmacists and client care
coordinators can work together to monitor the delivery of the medications. Further factors impacting
the treatment of HIV patients come into play when age and comorbidities such as diabetes,
hypertension, dyslipidemia and cardiovascular disease present.
The HIV population also has to combat challenges associated with socioeconomic factors such as
income, literacy level, coverage of costs of medications and treatment, proper housing, familial support

and/or stigmas associated with living with the disease. All of these challenges further necessitate the
discretion of delivery of services and medication so as clients remain protected and anonymous.

Thomas Ervin

Strategic Sales Specialist

561-708-6964